Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) ...

Genetic alterations lie at the heart of cancer development, but scientists may have been overlooking a powerful driver of these changes—the everyday nutrients that feed our cells.

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and ...

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity New study results ...

Adding ivonescimab to chemotherapy prolonged progression-free survival (PFS) in previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC), but failed to significantly improve overall ...

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a ...

How Well Does Tagrisso Work for Lung Cancer? The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several different scenarios. Tagrisso was studied in people who had lung ...

Getting a diagnosis of lung cancer can be scary, especially when you don't know what to expect. To help, experts will guide ...